Endoxan®

DRUG4 trials

Sponsors

NSABP Foundation Inc., Pfizer Inc., I.F.O. Istituti Fisioterapici Ospitalieri, Glaxosmithkline Research & Development Limited

Conditions

Patients with early breast cancermetastatic urothelial cancernewly diagnosed amyloid light chain amyloidosisrecurrent or refractory neuroblastomarecurrent/refractory Ewing sarcoma

Phase 1

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

CompletedCTIS2024-511975-14-00

Pfizer Inc.recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

Start: 2022-05-26End: 2025-08-06Target: 29Updated: 2025-09-08

Phase 2

PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phase 2 trial: minotaURO study

CompletedCTIS2024-514979-17-04

I.F.O. Istituti Fisioterapici Ospitalierimetastatic urothelial cancer

End: 2025-10-08Target: 43Updated: 2025-02-24

A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)

Not yet recruitingCTIS2025-522803-60-00

Glaxosmithkline Research & Development Limitednewly diagnosed amyloid light chain amyloidosis

Target: 17Updated: 2026-07-22

Phase 3

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"

CompletedCTIS2023-508472-11-00

NSABP Foundation Inc.Patients with early breast cancer

Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05